Program
toripalimab
Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 54 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Mabwell (Shanghai) Bioscience | 33 open or running | phase 3since Sep 9, 2024 | Sep 25, 2023 | Dec 31, 2026phase 2 · NCT06079112 |
| Coherus Oncology | 22 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| Suzhou Zelgen Biopharmaceuticals | 21 open or running | phase 2since Aug 3, 2020 | Aug 3, 2020 | none ahead |
| CSPC Pharmaceutical Group | 10 open or running | phase 3since Dec 12, 2018 | Dec 12, 2018 | none ahead |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2018First study: phase 3 study in Triple Negative Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03777579 · 375 enrolled · China
- Aug 3, 2020Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Advanced Hepatocellular CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT04503902 · 46 enrolled · China
- Oct 21, 2020Phase 1 study in Unresectable Hepatocellular CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT04605185 · 18 enrolled · China
- Mar 17, 2022RemeGen's first study: phase 2 study in Muscle Invasive Bladder CarcinomaNew to RemeGenRemeGen · NCT05297552 · 40 planned · China
- Sep 1, 2023Phase 2 study in Advanced Solid TumorRemeGen · NCT06038396 · 48 planned · China
- Sep 25, 2023Mabwell (Shanghai) Bioscience's first study: phase 2 study in Advanced Urothelial CarcinomaNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT06079112 · 100 planned · China
- Oct 23, 2023Phase 2 study in Breast NeoplasmsRemeGen · NCT06105008 · China
- Nov 23, 2023Phase 2 study in Stomach NeoplasmsRemeGen · NCT06155383 · 90 planned · China
- Jan 17, 2024Phase 2 study in Breast NeoplasmsRemeGen · NCT06227117 · 120 planned · China
- Jun 10, 2024Coherus Oncology's first study: phase 4 study in Nasopharyngeal NeoplasmsNew to Coherus OncologyCoherus Oncology · NCT06457503 · 100 planned · United States, Canada
- Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326 · 460 planned · China
- Oct 23, 2024Phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144 · 154 planned · United States, Taiwan
- Jan 13, 2025Phase 2 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06823427 · 60 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaMabwell (Shanghai) Bioscience · NCT06079112
- Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellMabwell (Shanghai) Bioscience · NCT06592326
- Dec 2027Primary completion: phase 4 study in Nasopharyngeal NeoplasmsCoherus Oncology · NCT06457503
- Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisCoherus Oncology · NCT06657144
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06823427Carcinoma, Transitional Cell · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Jun 2026 | 60 |
| NCT06657144Neoplasm Metastasis · United States, Taiwan | 1 | Recruiting | Coherus Oncology | Jan 2028 | 154 |
| NCT06592326Carcinoma, Transitional Cell · China | 3 | Recruiting | Mabwell (Shanghai) Bioscience | Sep 2027 | 460 |
| NCT06457503Nasopharyngeal Neoplasms · United States, Canada | 4 | Recruiting | Coherus Oncology | Dec 2027 | 100 |
| NCT06227117Breast Neoplasms · China | 2 | Recruiting | RemeGen | Dec 2025 | 120 |
| NCT06155383Stomach Neoplasms · China | 2 | Recruiting | RemeGen | Jan 31, 2025 | 90 |
| NCT06105008Breast Neoplasms · China | 2 | Withdrawn | RemeGen | Dec 20, 2025 | 0 |
| NCT06079112Advanced Urothelial Carcinoma · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2026 | 100 |
| NCT06038396Advanced Solid Tumor · China | 2 | Recruiting | RemeGen | Feb 28, 2026 | 48 |
| NCT05297552Muscle Invasive Bladder Carcinoma · China | 2 | Recruiting | RemeGen | Jun 1, 2024 | 40 |
| NCT04605185Unresectable Hepatocellular Carcinoma · China | 1 | Active, not recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2024 | 18 |
| NCT04503902Advanced Hepatocellular Carcinoma · China | 2 | UNKNOWN | Suzhou Zelgen Biopharmaceuticals | Dec 2023 | 46 |
| NCT03777579Triple Negative Breast Neoplasms · China | 3 | Suspended | CSPC Pharmaceutical Group | Dec 30, 2019 | 375 |
How it is read
Names in the registry
- “Toripalimab”, 14 entries
- “Toripalimab Injection”, 3 entries
- “CM082 plus JS001”, 3 entries
- “ABO2109 Injection;Toripalimab”, 2 entries
- “JS001”, 2 entries
Codes read as this program: JS001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 3 studies
- Melanoma, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Transitional Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.